CSIMarket
 


Vanda Pharmaceuticals Inc   (VNDA)
Other Ticker:  
 

Vanda Pharmaceuticals Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Vanda Pharmaceuticals Inc in the forth quarter 2023?
Vanda Pharmaceuticals Inc achieved a return on average equity (ROE) of 0.46 % in its forth quarter 2023, this is above VNDA's average return on equity of -3.41%.
Vanda Pharmaceuticals Inc shareholder's equity over the 12 months ending in its forth quarter 2023 are valued at $541 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Major Pharmaceutical Preparations industry 34 other companies had a higher return on equity. While Return on equity, overall ranking has advanced in the quarter, so far to 1575, from total ROE ranking in the third quarter 2023 at 1996.

What is ROE?



Return On Equity (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change 3.36 % 5.32 % 6.16 % 6.69 % -
Y / Y Net Income Change - -95.81 % -40.95 % - -3.07 %
Net Income (TTM) in Millions 3 12 15 16 6
Return On Equity (TTM) 0.46 % 2.19 % 2.81 % 3.06 % 1.22 %
VNDA's Total Ranking # 1575 # 1996 # 2062 # 1949 # 1834
Equity (TTM) in Millions 545 543 540 536 527
Seq. Equity Change 0.33 % 0.59 % 0.78 % 1.62 % 2.24 %
Seq. Net Income Change - -90.99 % -53.26 % -52.6 % 109.82 %

Return On Equity Company Ranking
Within: No.
Industry # 35
Sector # 128
Overall # 1575

Return On Equity Statistics
High Average Low
46.31 %
-3.41 %
-340.96 %
(March 31, 2015)   (Sep. 30, 2014)





VNDA Annual Return On Equity (Dec 31 2023)
2023
(Dec 31 2022)
2022
(Dec 31 2021)
2021
(Dec 31 2020)
2020
(Dec 31 2019)
2019
Total Equity in Millions 545 527 505 453 411
Y / Y Equity Change 3.36 % 4.41 % 11.4 % 10.3 % 49.21 %
Net Income in Millions 3 6 33 23 116
Y / Y Net Income Change -60.02 % -81.07 % 42.06 % -79.8 % 358.4 %
Return On Equity 0.46 % 1.19 % 6.57 % 5.15 % 28.12 %





Annual Roe Comment
In 2023 ROE decreased compared to the previous year to 0.46 %, due to deterioration of net income.


More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
VNDA's' Return on Equity at Yahoo Finance
VNDA's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Roe for VNDA's Competitors
Return On Equity for Vanda Pharmaceuticals Inc 's Suppliers
Roe for VNDA's Customers




Companies with similar Return On Equity at Dec 31 2023, within Healthcare Sector ROE
Vanda Pharmaceuticals Inc   0.46 %
Viatris Inc   0.26 %
Prime Medicine Inc   0.13 %


Date modified: 2024-02-08T15:38:22+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com